Beyond Conventional Anti-TIGIT: HanchorBio Secures Taiwan TFDA Approval for HCB303 Following U.S. FDA Clearance

Differentiated trispecific TIGIT-Fc ligand-trap strategy aims to address CD226 downregulation, a potential limitation of conventional anti-TIGIT antibodies U.S FDA clearance followed by accelerated Taiwan TFDA approval advances HCB303 toward multi-regional Phase 1 clinical development...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.